543. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review.
作者: Eliano P Navarese.;Michalina Kolodziejczak.;Dean J Kereiakes.;Udaya S Tantry.;Christopher O'Connor.;Paul A Gurbel.
来源: Ann Intern Med. 2016年164卷9期600-7页
Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) are an emerging therapy for dyslipidemia. Acute coronary events induce a dynamic increase of PCSK9 levels that may play a role in plaque vulnerability of both culprit and nonculprit coronary vessels. Growing evidence highlights a potential key role of PCSK9 antibodies in managing acute coronary syndrome. This review describes the influence of PCSK9 antibodies on plaque composition and instability, as well as the pharmacokinetic profile and the potential anti-inflammatory and antithrombotic mechanisms associated with PCSK9 inhibition that may confer benefits during the early phase of acute coronary syndrome. The authors posit a rationale for the use of PCSK9 antibodies in patients with acute coronary syndrome and highlight the need for further investigation in this area.
544. Gradual Versus Abrupt Smoking Cessation: A Randomized, Controlled Noninferiority Trial.
作者: Nicola Lindson-Hawley.;Miriam Banting.;Robert West.;Susan Michie.;Bethany Shinkins.;Paul Aveyard.
来源: Ann Intern Med. 2016年164卷9期585-92页
Most smoking cessation guidelines advise quitting abruptly. However, many quit attempts involve gradual cessation. If gradual cessation is as successful, smokers can be advised to quit either way.
|